Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List

NARecruitingINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

August 29, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

September 12, 2027

Conditions
Heart Failure
Interventions
OTHER

Biological sample for the measurement of suPAR levels.

Biological sample for the measurement of plasminogen activator receptor (suPAR) level at baseline and at 6 months follow up to assess the evolution of cardio-renal interaction in HF patients listed for heart transplant treated by GDMT including dapagliflozin.

Trial Locations (11)

31059

NOT_YET_RECRUITING

CHU de Toulouse, Toulouse

33600

NOT_YET_RECRUITING

CHU Bordeaux, Pessac

34295

NOT_YET_RECRUITING

CHU Montpellier, Montpellier

35033

NOT_YET_RECRUITING

CHU Rennes, Rennes

38700

NOT_YET_RECRUITING

CHU Grenoble, La Tronche

44093

NOT_YET_RECRUITING

Chu Nantes, Nantes

54500

RECRUITING

Chru Nancy, Vandœuvre-lès-Nancy

67091

NOT_YET_RECRUITING

CHU Strasbourg, Strasbourg

69500

NOT_YET_RECRUITING

Hospice Civil de Lyon - Hôpital Louis PRADEL, Bron

75015

NOT_YET_RECRUITING

Aphp Hegp, Paris

76031

NOT_YET_RECRUITING

Chu Rouen, Rouen

All Listed Sponsors
lead

Central Hospital, Nancy, France

OTHER

NCT06868797 - Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List | Biotech Hunter | Biotech Hunter